Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer
Copyright © 2023. Published by Elsevier GmbH..
BACKGROUND: This study employed a meta-analysis to evaluate the efficacy and safety of adjunctive treatment with injectable Lentinan (LNT) in combination with chemotherapy for gastric cancer (GC).
METHODS: Computer-based searches of 6 databases were performed to identify randomized controlled trials (RCTs) relevant to the treatment of GC with LNT through mid-March 2023. Two independent researchers performed risk of bias assessment and trial sequential analysis(TSA), extracted the data and used Revman 5.3 software for data analysis. The certainty of evidence was graded based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.
RESULTS: A total of 31 RCTs with 2729 patients were included in the analysis. The results revealed that adjunctive therapy with LNT was associated with improved treatment efficacy (RR = 1.48, 95%CI: 1.36 ∼ 1.61, p < 0.00001), improvement in clusters of differentiation (CD3+, CD4+, and CD4+/CD8+), natural killer (NK) cells, and quality of life assessment (RR = 1.32, 95%CI: 1.20 ∼ 1.45, p < 0.00001) compared to using chemotherapy alone. In addition, there was a reduction in CD8+ levels, incidence of white blood cell decline, gastrointestinal reactions, and platelet decline. TSA results indicated that there was sufficient evidence to draw firm conclusions about these outcomes, and the GRADE scores showed 'high' or 'moderate' quality of evidence for these outcomes.
CONCLUSION: The efficacy of treatment of GC with LNT in combination with chemotherapy was found to be better than chemotherapy alone. And no serious adverse effects were observed. However, further RCTs are needed to further validate the results of this study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:123 |
|---|---|
| Enthalten in: |
Phytomedicine : international journal of phytotherapy and phytopharmacology - 123(2024) vom: 17. Jan., Seite 155242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yixuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37339-90-5 |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 17.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phymed.2023.155242 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365916196 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365916196 | ||
| 003 | DE-627 | ||
| 005 | 20240117232108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phymed.2023.155242 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM365916196 | ||
| 035 | |a (NLM)38100922 | ||
| 035 | |a (PII)S0944-7113(23)00601-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yixuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 17.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier GmbH. | ||
| 520 | |a BACKGROUND: This study employed a meta-analysis to evaluate the efficacy and safety of adjunctive treatment with injectable Lentinan (LNT) in combination with chemotherapy for gastric cancer (GC) | ||
| 520 | |a METHODS: Computer-based searches of 6 databases were performed to identify randomized controlled trials (RCTs) relevant to the treatment of GC with LNT through mid-March 2023. Two independent researchers performed risk of bias assessment and trial sequential analysis(TSA), extracted the data and used Revman 5.3 software for data analysis. The certainty of evidence was graded based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach | ||
| 520 | |a RESULTS: A total of 31 RCTs with 2729 patients were included in the analysis. The results revealed that adjunctive therapy with LNT was associated with improved treatment efficacy (RR = 1.48, 95%CI: 1.36 ∼ 1.61, p < 0.00001), improvement in clusters of differentiation (CD3+, CD4+, and CD4+/CD8+), natural killer (NK) cells, and quality of life assessment (RR = 1.32, 95%CI: 1.20 ∼ 1.45, p < 0.00001) compared to using chemotherapy alone. In addition, there was a reduction in CD8+ levels, incidence of white blood cell decline, gastrointestinal reactions, and platelet decline. TSA results indicated that there was sufficient evidence to draw firm conclusions about these outcomes, and the GRADE scores showed 'high' or 'moderate' quality of evidence for these outcomes | ||
| 520 | |a CONCLUSION: The efficacy of treatment of GC with LNT in combination with chemotherapy was found to be better than chemotherapy alone. And no serious adverse effects were observed. However, further RCTs are needed to further validate the results of this study | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a Injectable Lentinan | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Systemic review | |
| 650 | 4 | |a Traditional Chinese medicine | |
| 650 | 7 | |a Lentinan |2 NLM | |
| 650 | 7 | |a 37339-90-5 |2 NLM | |
| 700 | 1 | |a Wang, Haojia |e verfasserin |4 aut | |
| 700 | 1 | |a Chai, Keyan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Siyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Yiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fanqin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jiaqi |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Zhengsen |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yifei |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Siyun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiaqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jiying |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Chuanqi |e verfasserin |4 aut | |
| 700 | 1 | |a Stalin, Antony |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jiarui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phytomedicine : international journal of phytotherapy and phytopharmacology |d 1994 |g 123(2024) vom: 17. Jan., Seite 155242 |w (DE-627)NLM093820402 |x 1618-095X |7 nnns |
| 773 | 1 | 8 | |g volume:123 |g year:2024 |g day:17 |g month:01 |g pages:155242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phymed.2023.155242 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 123 |j 2024 |b 17 |c 01 |h 155242 | ||